A pattern of disperse plaque microcalcifications identifies a subset of plaques with high inflammatory burden in patients with acute myocardial infarction  by Li, XiaoFei et al.
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Aims:  Inﬂammation  plays  a crucial  role  in  plaque  vulnerability.  Calciﬁcations  can  be  detected  by  means
of in  vivo  imaging  techniques.  The  study  purpose  is  to  assess  a potential  association  between  tissue
localization  of  calciﬁcations  and  the  inﬂammatory  biomarkers,  C-reactive  protein  (CRP),  osteopontin  and
lipoprotein-associated  phospholipase  A2 (Lp-PLA2),  in plaque  tissue  of patients  with  acute  myocardial
infarction  (AMI).
Methods and results:  Thrombectomy  materials  obtained  from  patients  with  electrocardiographically  docu-
mented  ST-segment  elevation  type  of AMI  (STEMI)  were  histologically  screened  for presence  of  thrombus,
plaque  tissues  and  calciﬁcations.  Size  of  calciﬁcations  was  measured  morphometrically,  and  their  colocal-
ization  with  the  inﬂammatory  biomarkers  macrophages,  CRP,  osteopontin  and  Lp-PLA2  was  assessed  with
immunostaining.  A  total  of  171  samples  containing  plaque  tissues  were  obtained  from  562  thrombectomy
procedures.  Calciﬁcations  were  observed  in  67  (39%)  plaque  fragments,  with  diameters  ranging  from  4 to
170  m.  Plaque  tissues  with  calciﬁcations  contained  more  frequently  extracellular  CRP  and  intracellular
CRP  in  macrophages  than  those  without  calciﬁcations  (85%,  59% vs. 64%, 32%, P  =  0.012  and  0.005  respec-
tively).  Similar  results  were  obtained  with  osteopontin  immunostaining  (98%,  76% vs.  56%,  40%;  P  < 0.001
both).  Furthermore,  samples  with  calciﬁcations  were  immunostained  for CRP  more  intensely  than those
without  calciﬁcations  (P  = 0.001).  Finally,  96%  of the  plaque  tissues  stained  positively  for Lp-PLA2,  but
there  was  no  association  with  presence  of  microcalciﬁcations.
Conclusions: A  pattern  of  disperse  microcalciﬁcations  is positively  associated  with  presence  of  the  inﬂam-
matory  biomarkers  macrophages,  CRP and  osteopontin  in  thrombectomy  materials  of  STEMI  patients.
Based  on  these  ﬁndings,  we speculate  that such  microcalciﬁcations  could  have  the  potential  to  serve  as
a surrogate  marker  for plaques  with  high  inﬂammatory  burden.. Introduction
By far most cases of acute myocardial infarction (AMI) result
rom coronary thrombus formation superimposed on disruption
f a vulnerable type of atherosclerotic plaque [1]. Many studies
ave shown that the vulnerability to rupture is usually not a fea-
ure of a single (culprit) plaque, but may  involve several plaques
Abbreviations: ARedS, Alizarin red S stain; AMI, acute myocardial infarction;
RP,  C-reactive protein; EBCT, electron beam computed tomography; hsCRP, high
ensitivity CRP; IVUS, intravascular ultrasound; Lp-PLA2, lipoprotein-associated
hospholipase A2; OPN, osteopontin; PCI, percutaneous coronary intervention;
TEMI, ST-segment elevation myocardial infarction.
∗ Corresponding author at: Post Ofﬁce Box 22660, 1100 DD Amsterdam, The
etherlands. Tel.: +31 20 5665715; fax: +31 20 5669523.
E-mail addresses: x.li@amc.uva.nl, harbinfei@hotmail.com (X. Li).
021-9150 © 2011 Elsevier Ireland Ltd.  
oi:10.1016/j.atherosclerosis.2011.04.032
Open access under the Elsevier OA license.© 2011 Elsevier Ireland Ltd. 
in the coronary system of a patient (pan coronary vulnerability)
[2]. Such insights have boosted the search for in vivo markers of
plaque vulnerability, by means of high resolution coronary imag-
ing techniques or serum levels of inﬂammatory proteins, to identify
patients with increased cardiovascular risk.
Calciﬁcation is an excellent marker for the presence of
atherosclerosis, but its role on plaque instability is still unclear.
Although coronary calciﬁcations detected by electron beam com-
puted tomography (EBCT) is strongly predictive for adverse
cardiovascular outcome [3,4], severe calciﬁcation is not a feature
of coronary luminal narrowing and plaque instability [5,6]. More-
over, a systematic autopsy study on coronary arteries of sudden
Open access under the Elsevier OA license.coronary death victims revealed that the majority of acute ruptured
and thrombosed plaques is only mildly calciﬁed [6].  In addition,
a recent in vivo study by using intravascular ultrasound (IVUS)
suggested that not the degree, but the pattern of calciﬁcations
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multiple, small calcium deposits) could be associated with plaque
nstability [7].
In  contrast to calciﬁcation, inﬂammation plays a crucial role
n plaque vulnerability [8].  Numerous intraplaque inﬂammatory
roteins are capable of degrading the ﬁbrous cap, which may  even-
ually lead to plaque rupture and thrombosis. Furthermore, several
nﬂammatory biomarkers have been elucidated that are associ-
ted with adverse cardiovascular outcome, of which particularly
-reactive protein (CRP), osteopontin (OPN) and lipoprotein-
ssociated phospholipase A2 (Lp-PLA2) appear to have a strong
redictive value [9–14].
With the development of high resolution intravascular imag-
ng techniques, several histological characteristics of vulnerable
laques (thickness of ﬁbrous cap, size of necrotic core) can be iden-
iﬁed and quantiﬁed in vivo; but detection of the “vulnerability
arker” intraplaque inﬂammation is still a problem that needs
o be resolved in clinical practice [15]. In contrast to intraplaque
nﬂammation, calciﬁcations are an excellent marker of atheroscle-
otic plaques and can be visualized even in micro-dimensions with
se of high resolution image techniques [16]. Dystrophic calciﬁca-
ion typiﬁes many chronic inﬂammatory processes in the human
ody [17], but a putative relationship between presence of calci-
cations and pro-inﬂammatory tissue markers has not yet been
tudied in vivo in the culprit lesions of AMI  patients. This could be
f interest, since hypothetically, distinct patterns of calciﬁcations
ay  serve as a surrogate marker of plaque inﬂammatory activity.
ST-segment elevation myocardial infarction (STEMI) is a sub-
et of AMI and characterized by severe transmural necrosis and
igh short-term mortality [18,19]; as results of which emergent
evascularization treatment of the occluded coronary artery is rec-
mmended for patients with STEMI by means of thrombectomy
djunctive to percutaneous coronary intervention (PCI) [20]. Mate-
ials retrieved from thrombectomy appear suitable for histological
tudy, since they have been shown to contain plaque fragments
rom culprit lesions of STEMI patients (in addition to thrombus)
n up to 40% of cases [21]. In the present study we investigated the
elationship between distinct morphologic patterns of plaque calci-
cations and the intraplaque immunolocalization of macrophages,
RP, osteopontin and lipoprotein-associated phospholipase A2 (Lp-
LA2) with use of the thrombectomy materials.
. Materials and methods
.1. Patient population
Between January 2005 and December 2006, a total of 562
atients were treated with thrombectomy adjunctive to primary
CI. Patients were eligible if there was evidence of acute myocar-
ial infarction with ST segment elevation of ≥0.2 mV in two
r more contiguous leads on the admission electrocardiogra-
hy and symptoms of <24 h’ duration. Thrombectomy procedures
ere performed as previously described [21]. On admission, all
he patients received aspirin 300 mg  and unfractionated heparin
000–10,000 IU. Clopidogrel was administered in a loading dose of
00 or 600 mg  directly before or immediately after the procedure
nd was prescribed for at least 1 month. The use of glycoprotein
Ib/IIIa inhibitors and antithrombotic medications was  at the dis-
retion of operators. After access into the femoral artery, the ﬂexible
hrombectomy catheter was advanced in the infarct-related coro-
ary artery. Before balloon dilatation or stent implantation, several
uctions were performed at the site of culprit lesions. The aspi-
ated materials were collected in the collection bottle, which could
e used for this study. Information with respect to cardiovascu-
ar risk factors was obtained at bedside in the catheterization unit.
erum hsCRP values, measured on admission, were obtained from
he electronic hospital record.Fig. 1. Selection of study materials. Thrombectomy materials obtained during pri-
mary  PCI were screened and divided into two groups based on presence or absence
of  calciﬁcations.
2.2. Selection of thrombectomy materials
All the aspirated materials were placed in 10% neutral
buffered formalin immediately after retrieval, ﬁxed for at least
24 h and embedded in parafﬁn. Six-micrometer-thickness sec-
tions were stained with hematoxylin and eosin stains (H&E
stain) for histopathological observations including identiﬁcation
of calciﬁcations. Adjacent tissue sections were stained immuno-
histochemically for evaluation of the intraplaque inﬂammatory
biomarkers. Size of samples was measured macroscopically on
glass slices. Only samples of ≥1 mm2, and of those only the sam-
ples that contained histologically conﬁrmed atherosclerotic plaque
tissues, were enrolled in this study (see Fig. 1).
2.3. Morphometric analysis of tissue calciﬁcations and
visualization of colocalization between calciﬁcations and
macrophages
Morphometric analysis of calciﬁcations was  performed on
Alizarin red S (ARedS) stained sections. Immuno-enzyme dou-
ble staining with anti-HAM56 antibody (1:50, Dako, Glostrup,
Denmark) and ARedS was used to study the colocalization between
calciﬁcations and macrophages. Images of calciﬁcations were
acquired at ×100 magniﬁcation using a Leica DFC500 digital cam-
era mounted on a Leica DM 5000 microscope. Measurement of
calciﬁcations was  performed automatically by using computer-
based image software (Image Pro Plus 5.0, Media Cybernetics). Only
the particles ≥4 m were measured for ﬁnal evaluation, which is
around the minimum range of detection of current high resolution
imaging techniques.
2.4. Evaluation of CRP, OPN and Lp-PLA2 immunostainingPresence of intraplaque CRP or Lp-PLA2 was evaluated with
immunodouble staining combining anti-CRP antibody (rabbit
monoclonal Y284, 1:500, Abcam, Cambridge, UK) or anti-Lp-
PLA2 antibody (rabbit polyclonal HPA018157, 1:20, Sigma, St.
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Table  1
Patient clinical characteristics.
Calciﬁcation (67) Non-calciﬁcation (104) P-value
Gender (male) 68.7% 76.9% 0.29
Age  (years; mean, ±SD) 63.5 ± 12.1 63.1 ± 13.2 0.82
Diabetes mellitus 14.1% 22.1% 0.28
Hypertension 37.3% 35.6% 0.87
Dyslipidemia 50.0% 54.8% 0.80
Current smoker 43.1% 42.2% 1.00
Previous myocardial infarction 38.8% 31.8% 0.41
Statin 39.4% 33.7% 0.51
BMI  (kg/m2; median,
range)
25.6 26.1 0.16
17.7–47.8 18.8–41.2
Serum hsCRP (mg/l;
median, range)
3.8 2.6 0.24
0.4–71.1 0–98.1
Pre-infarct unstable angina 28.6% 18.8% 0.22
Event  to balloon time (min;
median, range)
184.5 185.0 0.95
75.0–959.0 64.0–844.0
Location of lesions
RCA 50.8% 50.5% 0.976
LCA 44.6% 45.5%
LCx  4.6% 4.0%
Size of materials (mm;
median, range)
3.0 3.5 0.81
1.0–11.0 1.0–18.0
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8ontinuous variables are expressed as mean ± SD or median with range. Categoric
rtery,  LCx: left circumﬂex; BMI: body mass index; hsCRP: high sensitive C-reactive
ouis, USA) with anti-CD68 antibody (mouse monoclonal PG-
1,  1:100, Dako). Intraplaque OPN was analyzed with the use
f immunotriple staining combining anti-OPN antibody (rabbit
olyclonal 1:1000, Abcam), anti-smooth muscle actin (mouse mon-
clonal 1A4, 1:2000, Dako) and anti-CD68 antibody (PG-M1, 1:500,
ako). Double and triple staining methods were used as previ-
usly described [22]. Diaminobenzidine (DAB, Dako), Vector Blue
nd Vector Red substrate kits (Vector Laboratories) were applied
s chromogens. Negative controls were performed by replacing the
rimary antibodies with non-immune IgG of similar species, sub-
lass and concentration. Steatotic liver tissue was used as positive
ontrol for CRP stain, cerebral tissue for Lp-PLA2 stain and post-
ortem coronary atherosclerotic plaque served as positive control
or OPN stain.
In each thrombectomy sample, CRP, Lp-PLA2 and/or OPN
mmunostaining was evaluated as either present or absent, and cor-
elated with presence of calciﬁcation in the samples. Furthermore,
ntensity of extracellular CRP and Lp-PLA2 staining was  graded into
 categories: 0 (negative), 1 (mild positive staining) and 2 (strong
ositive staining).
.5. Statistics
Statistical analysis was performed with SPSS 11. Results are
xpressed as mean ± SD or median with range. In case the data were
ormally distributed, the 2 groups were compared with unpaired
 test. Comparison of non-normal distributed data of two indepen-
ent groups, Mann–Whitney test was used and the Kruskal–Wallis
est was used for ≥3 independent groups. Categorical data were
xpressed as percentage and evaluated with 2 test. A P-value of
0.05 was considered statistically signiﬁcant.
. Results
.1. Patient clinical characteristicsFig. 1 shows the ﬂow chart for selection procedure of study
aterials. Histologically conﬁrmed materials were obtained from
2% (460/562) of all the thrombectomy procedures. Majority (63%,ables are expressed as percentages. RCA: right coronary artery, LCA: left coronary
in.
289/460) of the materials are composed exclusively of thrombus,
whereas 37% (171/460) of the materials consist of both thrombus
and atherosclerotic plaque tissue. Only the thrombectomy materi-
als containing plaque tissues (n = 171) were included in the current
study. Of these, calciﬁcations were present in 39% (67/171) and
absent in 61% (104/171) of the samples.
Patient characteristics were summarized in Table 1. There were
no differences in major risk factors for cardiovascular diseases,
in medication or serum hsCRP values between the patients with
calciﬁcations in the thrombectomy materials and those without
calciﬁcations. The interval from onset of symptom to opening of
vessels was  in 96% of the patients within 12 h and no difference
was found between the study groups (P = 0.95). Pre-infarct unsta-
ble angina, deﬁned as unstable angina of <30 min in the proceeding
2 weeks, was  observed in 23% of all the patients and there was  no
difference between the two  study groups (P = 0.22).
3.2. Calciﬁcation score in plaque tissue
All together, a total of 1699 calcium particles were measured
in the sections that contained calciﬁcations. Calciﬁcations in the
samples were disperse microcalciﬁcations with diameters ranging
from 4 m to 170 m and a median of 9 m (Fig. 2A and B).
3.3. In situ colocalization of calciﬁcations with plaque cells,
C-reactive protein, osteopontin and lipoprotein-associated
phospholipase A2
Immunohistochemistry was used to compare the in situ pres-
ence of inﬂammatory biomarkers in plaque tissues containing
microcalciﬁcations with those without microcalciﬁcations. Because
of the limited size of aspirated samples, only 119/171 (70%) of the
selected thrombectomy materials were available for CRP staining,
115/171 (67%) for OPN staining and 45/171 (26%) thrombectomy
samples were available for Lp-PLA2 staining. CD68+ foam cells were
nearly always located inside lipid rich plaque tissue in both groups
(93% of tissues with microcalciﬁcations and 86% of tissues without
microcalciﬁcations, P = 0.38).
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Cig. 2. Morphometric analysis of calciﬁcations. (A) Immuno-enzyme double stain
tained in red as shown with arrows and macrophages stained in blue. (B) Pooled d
nterpretation of the references to color in this ﬁgure legend, the reader is referred 
If present, extracellular CRP staining was found throughout
ipid plaque tissue (Fig. 3A–C), whereas extracellular OPN stain-
ng appeared bound to microcalciﬁcations (Fig. 3E). Immunotriple
taining with anti-CD68, anti-smooth muscle actin and anti-
PN antibodies showed that cytoplasmic OPN was present in
acrophages only, and not in smooth muscle cells. As shown in
able 2, both intra- and extracellular immunostaining of CRP and
PN was found more frequently in plaque tissues with micro-
alciﬁcations than those without microcalciﬁcations (P < 0.05 for
ll). Furthermore, intensity of CRP immunostaining was  greater in
amples with microcalciﬁcations than those without microcalciﬁ-
ations (P = 0.001, Fig. 3D).
Immunostainable Lp-PLA2 was present in 96% of plaque tis-
ues containing thrombectomy samples, strictly localized in the
reas with extracellular lipid and macrophages (vulnerable plaque
issue) (Fig. 3F). However, there were no differences observed in
resence (Table 2) or staining intensity of Lp-PLA2 between calciﬁed
nd non-calciﬁed plaque tissues (P = 0.15).
. Discussion
Thrombectomy adjunctive to primary PCI, which is currently
he treatment of choice for patients with STEMI in our institu-
ion, provides a unique opportunity to retrieve large numbers
f tissue samples from culprit atherosclerotic lesions related to
nset myocardial infarction. In the present study we  demonstrated
hat thrombectomy materials can be used as ex vivo materi-
ls for histopathological investigation of potential biomarkers for
laque vulnerability in STEMI patients. The primary results of this
tudy show that disperse calcium deposits with dimensions of
able 2
verview of results.
Calciﬁcation group
Calciﬁcation diameters (m;  median, range) 9, 4–170
Macrophages 93% (49/53) 
Extracellular CRP 85% (45/53) 
Intracellular CRP in macrophages 59% (31/53) 
Extracellular OPN 98% (49/50) 
Intracellular OPN in macrophages 76% (38/50) 
Smooth muscle cells 32% (16/50) 
Extracellular Lp-PLA2 96% (22/23) 
Intracellular Lp-PLA2 in macrophages 61% (14/23) 
ontinuous variables are expressed as median with range. Categorical variables are expr
-reactive protein; OPN indicates osteopontin; Lp-PLA2 indicates lipoprotein-associated ith anti-HAM56 antibody and Alizarin Red S (×200 magniﬁcation). Calciﬁcations
diameters of all the measured calciﬁcations; range: 4–170 m;  median: 9 m. (For
 web version of the article.)
microcalciﬁcations (median = 9 m,  range 4–170 m), can be found
in 39% of the thrombectomy samples containing plaque tissues, and
are strongly associated with immunostaining of the biomarkers for
cardiovascular risk CRP and OPN in plaque tissues, but not Lp-PLA2.
4.1. Microcalciﬁcations in culprit lesions of STEMI patients
Although calciﬁcation is a well-known feature of coronary
atherosclerotic plaques, its potential role in onset of plaque insta-
bility remains controversial. An autopsy study by Sangiorgi et al.
showed that coronary calciﬁcation was  proportional to overall
plaque burden, but was  not associated with the severity of anatomic
stenosis [5].  However, with the introduction of EBCT, coronary cal-
ciﬁcation can be analyzed quantitatively in vivo, and several clinical
studies have shown that the EBCT-derived coronary calcium score
can be considered as a strong predictor of adverse cardiovascular
prognosis, even in asymptomatic patients [3,4]. Also size of calci-
ﬁcations seems to be important. Virmani et al. [6,23] revealed that
calciﬁcations in 65% of acute ruptured plaques of sudden coronary
death victims were radiographically so-called “speckled calciﬁca-
tions”. Similar results were obtained by Ehara et al. [7] who, with
use of IVUS, compared calciﬁcations in culprit lesions of acute coro-
nary syndromes with those of chronic stable angina. They observed
multiple, small calcium deposits (so-called “spotty calciﬁcations”)
in the tissues of patients with acute coronary syndromes, in con-
trast to patients with stable angina who had only few but large
calciﬁcations. Our ﬁndings of disperse microcalciﬁcations in 39%
of the thrombectomy specimens containing plaque tissues which
are all obtained from culprit plaques underlying STEMI, conﬁrm
 Non-calciﬁcation group P-value
86% (57/66) 0.38
64% (42/66) 0.012
32% (21/66) 0.005
56% (36/65) <0.001
40% (26/65) <0.001
43% (29/65) 0.18
96% (21/22) 1
46% (10/22) 0.38
essed as percentages. Chi-square test is used for statistical analysis. CRP indicates
phospholipase A2.
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Fig. 3. Immunostaining for intraplaque inﬂammatory biomarkers: macrophages, C-reactive proteins (CRP), osteopontin (OPN) and lipoprotein-associated phospholipase A2
(Lp-PLA2). (A) Negative CRP staining: no CRP immuno-activity; only macrophages stained in red (low power view of ×40 magniﬁcation). “T” indicates thrombus compartment;
“Pl”  indicates plaque compartment. (B) Mild positive CRP staining: CRP stained in light blue and macrophage stained in red. (C) Strong positive CRP staining: CRP stained
diffusely in dark blue; arrow shows macrophage with intracellular CRP stained in purple. (D) Extracellular CRP in atherosclerotic plaques was signiﬁcantly more intensely
stained in samples with microcalciﬁcations compared those without microcalciﬁcations (P = 0.001). Chi-square test is used for statistical analysis. (E) Extracellular osteopontin
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itained in red and macrophages in brown (×200 magniﬁcation). Arrow shows mac
nd  anti-CD68 antibody (×200 magniﬁcation). Extracellular Lp-PLA2 stained in b
nterpretation of the references to color in this ﬁgure legend, the reader is referred 
nd extend these previous observations by measuring precisely the
ange of sizes of the microcalciﬁcations in plaque tissues.
Moreover, such microcalciﬁcations could play an active role in
he process of plaque destabilization prior to rupture. A recent
n vitro study suggested that microcalciﬁcations with a diameter
f 1 m or less could lead to apoptosis of human vascular smooth
uscle cells, and these cells are considered to play a protective role
n plaque stability [24]. In addition, several studies demonstratedge with intracellular OPN. (F) Immunodouble staining with anti-Lp-PLA2 antibody
d macrophage in red, arrow shows macrophage with intracellular Lp-PLA2. (For
 web  version of the article.)
that that minute cellular-level calcium particulates could increase
local stress in ﬁbrous cap and lead to plaque rupture [25,26].
4.2. Association between calciﬁcation and inﬂammatory
biomarkers
The concept that inﬂammation plays a crucial role in plaque
vulnerability is widely accepted [8],  and the application of
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nﬂammatory biomarkers as tools in cardiovascular risk stratiﬁ-
ation has become a hotspot. Among all the biomarkers, the acute
hase protein CRP is studied most extensively and considered to be
 robust predictor of poor cardiovascular outcome [9–11]. Several
linical studies have investigated the putative relationship between
erum CRP levels and coronary calciﬁcation. In the Framingham
eart Study a positive association was reported between level of
RP in the blood and subclinical coronary calciﬁcation detected
oor EBCT [27]. In contrast, the SIRCA study showed that serum
sCRP was not at all associated with coronary calciﬁcations in
en, and only weakly in women [28]. The present study also did
ot reveal any difference in serum hsCRP levels between patients
ith- and without plaque microcalciﬁcations in their thrombec-
omy materials. But, when we applied CRP-immunostaining on the
ame specimens of all the patients, it was shown that the plaque
issues with microcalciﬁcations contain more frequently immunos-
ainable CRP, including CD68+ macrophages with intracytoplasmic
RP. Moreover, the extracellular CRP was immunostained more
ntensely in the plaque tissues with microcalciﬁcations than those
ithout microcalciﬁcations. These ﬁndings showed that CRP inside
he plaques associated with microcalciﬁcations appears to be a far
ore common feature as can be appreciated from measurement of
erum hsCRP levels. Still such low levels of intraplaque CRP synthe-
is can be of relevance, since CRP exerts several pro-inﬂammatory
ffects inside the plaque [29], which may  further increase plaque
ulnerability.
Osteopontin (OPN) is another important biomarker and strongly
ssociated with poor cardiovascular prognosis [12]. In addition,
PN plays an important role in migration of macrophages and
nhibits ectopic calciﬁcation in human body [30,31].  Similar to
ur results on CRP immunostaining, we found a positive associa-
ion between extracellular immunostainable OPN, OPN containing
acrophages and the presence of microcalciﬁcations in plaques.
uch observations endorse the outcome of recent in vitro stud-
es on macrophages co-cultured with calcium particles, which
evealed that microcalciﬁcations induce a proinﬂammatory effect
n macrophages, as became evident by their secretion of proinﬂam-
atory cytokines [32].
Lp-PLA2, as a calcium-independent phospholipase A2, is another
ovel inﬂammatory biomarker. Serum levels and in situ expression
n carotid atherosclerosis of Lp-PLA2 are positively associated with
dverse cardiovascular outcomes, independently of traditional risk
actors [13,14]. We  found positive Lp-PLA2 immunostaining in
early all the plaque fragments containing extracellular lipid and
acrophages (the vulnerable plaque components), which illus-
rates the importance of the protein as a biomarker. However, in
ontrast to our ﬁndings on CRP and OPN, we found no positive
ssociation between presence of microcalciﬁcations and plaque
p-PLA2 immunopositivity, so apparently a pattern of disperse
icrocalciﬁcations cannot serve as a surrogate marker for in situ
resence of this protein.
. Conclusion
In this study we have shown that when microcalciﬁcations are
resent in plaque fragments of STEMI patients, they frequently
olocalize with the inﬂammatory biomarkers CRP and OPN; as
uch, a subgroup of plaques with high inﬂammatory burden can
e identiﬁed. As a future perspective, we may  speculate that these
icrocalciﬁcations in plaques, which can be detected by means of
arious in vivo imaging techniques, could serve as a potential sur-
ogate marker for intraplaque inﬂammatory activity. However, the
pplication of the microcalciﬁcations as a marker for plaque insta-
ility needs to be conﬁrmed, since the sensitivity, speciﬁcity and
redictive value of this marker is still undeﬁned without compar-
tive data on non-culprit lesions.
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